Case study

Guilford

Building a drug development process for the future

Guilford, a small pharmaceutical company focusing on research into neurological and neuro-protective drugs, needed to increase the size and scope of its drug development but lacked the financial resources and clinical, corporate experience to do so. PA helped develop the ‘B2B1000 initiative’, enabling the company to take its first and subsequent products ‘from bench to bedside’ in 1,000 days or less.